'Inflationary Pressures Continue To Impact" Cannabis Industry, Says C21 As It Reports Net Loss And Decline In Nevada Sales
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Aug 16 2024
0mins
Should l Buy ?
Source: Benzinga
Financial Performance: C21 Investments reported a revenue of $6.6 million for the first quarter ending June 30, 2023, marking a slight increase despite a 1% decline in Nevada sales, with gross margins affected by inventory issues related to the launch of a new dispensary.
Operational Highlights: The company experienced a net loss of $1.4 million but maintained positive cash flow from operations and completed the acquisition of a third dispensary, which was rebranded and became operational at the end of the quarter.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
